EGFRt/19-28z/IL-12 CAR T Cells therapy(Roswell Park Cancer Institute)

N/A

Report date: 2025/08/05 20:00:05

Base Information

Drug NameEGFRt/19-28z/IL-12 CAR T Cells therapy(Roswell Park Cancer Institute)

Drug Alias NameCD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularPlasmablastic Lymphoma +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRoswell Park Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRoswell Park Cancer Institute

Active IndicationsN/A

Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularPlasmablastic Lymphoma +[7]

Other Information

ATC CodeN/A